Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Baraclude

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

Bristol-Myers Squibb (BMS) building

BMS takes option to buy fibrosis firm Galecto

The Swedish biotech has a pulmonary fibrosis candidate in early-stage testing

- PMLiVE

BMS expand biologics manufacturing deal with Lonza

Will make wider use of New Hampshire facilities ahead of product launch

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

The pharma business environment in the US

Tighter regulations, more pricing controls and increased international competition will drive market improvements

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links